We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

69 hedge funds and large institutions have $270M invested in Albireo Pharma Inc in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 8

75% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 12

38% more funds holding

Funds holding: 50 → 69 (+19)

27% more capital invested

Capital invested by funds: $213M → $270M (+$56.6M)

Holders
69
Holders Change
+19
Holders Change %
+38%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
21
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$14.5M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$8.95M
3
State Street
State Street
Massachusetts
+$4.54M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$3.49M
5
Northern Trust
Northern Trust
Illinois
+$2.72M

Top Sellers

Rank Fund Capital Flow
1
AWG
Alpha Wave Global
New York
-$5.7M
2
DZ Bank
DZ Bank
Germany
-$2.04M
3
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$1.97M
4
Millennium Management
Millennium Management
New York
-$1.67M
5
AG
Artal Group
Luxembourg
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
51
Bank of Montreal
Ontario, Canada
$156K +$2.1K +65 +2%
MLICM
52
Metropolitan Life Insurance Company (MetLife)
New York
$118K +$108K +3,328 New
JP Morgan Chase
53
JP Morgan Chase
New York
$111K +$101K +3,111 New
SO
54
STRS Ohio
Ohio
$95K +$87.5K +2,700 New
PCM
55
Prelude Capital Management
New York
$72K -$17.3K -533 -21%
Citigroup
56
Citigroup
New York
$61K +$55.3K +1,708 New
Bank of America
57
Bank of America
North Carolina
$54K +$2.1K +65 +4%
TDC
58
Thompson Davis & Co
Virginia
$49K -$4.05K -125 -8%
Legal & General Group
59
Legal & General Group
United Kingdom
$48K +$44K +1,359 New
Wells Fargo
60
Wells Fargo
California
$40K -$162K -4,997 -82%
TRCT
61
Tower Research Capital (TRC)
New York
$34K +$30.9K +955 New
AIP
62
Ameritas Investment Partners
Nebraska
$24K +$22.3K +688 New
Barclays
63
Barclays
United Kingdom
$23K -$169K -5,226 -89%
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$10.7K +$9.72K +300 New
Royal Bank of Canada
65
Royal Bank of Canada
Ontario, Canada
$7K +$2.49K +77 +77%
PIA
66
Piedmont Investment Advisors
North Carolina
$6K +$5.12K +158 New
VIA
67
Vantage Investment Advisors
Pennsylvania
$4K -$3.24K -100 -50%
PMFA
68
Plante Moran Financial Advisors
Michigan
$2K – – –
AWG
69
Alpha Wave Global
New York
– -$5.7M -175,000 Closed
DZ Bank
70
DZ Bank
Germany
– -$2.04M -62,647 Closed
Susquehanna International Group
71
Susquehanna International Group
Pennsylvania
– -$1.02M -31,415 Closed
BCM
72
BlueCrest Capital Management
Jersey
– -$709K -21,775 Closed
TEE
73
Tibra Equities Europe
United Kingdom
– -$590K -18,101 Closed
ECM
74
Element Capital Management
New York
– -$335K -10,283 Closed
CS
75
Credit Suisse
Switzerland
– -$226K -6,939 Closed
1 2
3
4

ALBO Hedge Fund Activity: Q2 2018 in Review

69 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2018, worth a combined $270M — up 27% from $213M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ALBO positions and 8 closed out — a net gain of 19 holders — while 21 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $14.5M. The largest seller was Alpha Wave Global, exiting entirely with an estimated $5.7M sold.

  • 69 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2018, up from 50 in Q1 2018.
  • Funds reported $270M of Albireo Pharma Inc stock for Q2 2018, up 27% quarter-over-quarter.
  • 27 funds opened new Albireo Pharma Inc positions in Q2 2018 and 8 closed out, a net change of +19 holders.
  • The largest Albireo Pharma Inc buyer in Q2 2018 was BlackRock, an estimated $14.5M added.
  • The largest Albireo Pharma Inc seller in Q2 2018 was Alpha Wave Global, an estimated $5.7M sold.

Based on aggregated 13F filings for Q2 2018.